Identification of Transition-State Analogue Inhibitors of Purine Phosphoribosyl transferases of Parasitic Protozoa by Target-Guided Screening - PROJECT SUMMARY The etiological agents of Chagas disease (CD) (Trypanosoma cruzi) and malaria (mainly Plasmodium falciparum) require purine base salvage from their hosts for viability. The absence of effective therapies and optimized vaccines, and the continuing emergence of drug resistance for both diseases, underscores the critical need for drug discovery for these neglected tropical diseases. Hypoxanthine-guanine-xanthine (purine) phospho- ribosyltransferases (PPRTs) catalyze the conversion of of the eponymous purine bases to IMP, GMP, and XMP, and are essential for parasite survival. From a five-year collaboration, transition-state analogue inhibitors (TSAIs; Ki = 0.2-7.5 nM) were identified for these five protozoal PPRTs in which structural features of transition-state mimicry include one protonated nitrogen at the N7 position of the purine analogue, and another replacing the putative ribocation at C1' of the ribose ring. These inhibitors contain phosphonate groups, which, while essential for PPRT inhibition, retard entry into infected cells. Attempts to ablate their negative charges by making phospho- diester prodrugs or by installing neutral isosteres of the phosphonate groups were unsatisfactory. In this proposal, target-guided screening (TGS) will be used to find neutral replacements for the phosphonate groups while retaining the transition-state character of our inhibitors. In this innovative method, three purine analogues (9-deaza-9-formyl-purine, 9-deaza-9-aminomethyl-purine, and 9-deaza-9-ethynaminomethyl-purine), all of which contain the structural elements of transition-state mimicry, will serve as “anchor ligands” bound to the purine binding sites of PPRTs in separate studies. The three PPRT-purine complexes are then incubated with small libraries of chemically-complementary compounds (MW < 300), which are respectively: amines, aldehydes/ketones, and azides. Due to available crystal structures of PPRT-purine analogue complexes, in silico screening of libraries of amines, aldehydes, ketones, and azides will first be conducted to filter out those compounds that will not form ternary complexes with the PPRT-purine analogue complexes. Library members that are accepted by the PPRTs in unoccupied PPRT subsites will form covalent adducts with these anchor purines, which will then be characterized by native mass spectrometry or LCMS. Due to their retained transition- state character, these enzyme-directed, covalent adducts will likely be potent inhibitors and contain new substituents replacing the phosphonate groups. They will be re-synthesized by facile synthetic chemistry, and evaluated as PPRT inhibitors. Purified trypanosomal kinases were found to catalyze phosphorylation of the anti- leukemia drug Forodesine, a picomolar inhibitor of purine nucleoside phosphorylase. 5'-Phospho-Forodesine is a potent inhibitor of PPRTs (Ki = 1-13 nM). Other purine nucleoside analogues and alcohols found in TGS are potential substrates for these protozoal adenosine kinases. As nucleoside analogues, they are likely to be uptaken by nucleoside transporters in protozoa and then converted into phosphates, and thereby into PPRT inhibitors. Inhibitors from both approaches will be evaluated in cellular models of CD.